STING1 and ovarian carcinoma: This miR-181a-STING axis drives both PARPi resistance and cross-resistance to platinum-based chemotherapy, making it a promising biomarker and therapeutic target to overcome drug resistance in BRCA-mutated ovarian cancer (45).